The meeting outlined the evidence that the use of magnetic resonance imaging (MRI) markers as surrogate endpoints in clinical trials of relapsing-remitting multiple sclerosis (MS) is both valid and informative.
Emerging Treatment Strategies for Motor Fluctuation Management: Therapeutic Options for Newly Detected Motor Fluctuations
6 Mins
